# Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

> **NCT05656443** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fujian Akeylink Biotechnology Co., Ltd.** · enrollment: 1246 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** GST-HG171/Ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05656443
- **Lead sponsor:** Fujian Akeylink Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-19
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-07-14
- **Target enrollment:** 1246 (ACTUAL)
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656443, "Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05656443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*